Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.66 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL27634053 | 0.94 | OPRM1 (0.72) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL31114332 | 0.92 | OPRM1 (0.70) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL4576363 | 0.91 | OPRM1 (0.63) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL4576369 | 0.91 | OPRM1 (0.63) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL30353452 | 0.90 | OPRM1 (0.62) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL30122975 | 0.89 | OPRM1 (0.65) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL31114383 | 0.88 | OPRM1 (0.68) | OPRM1NTSR2NTSR1SORT1F2 | |
| SCHEMBL31091680 | 0.87 | OPRM1 (0.64) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL31167614 | 0.87 | OPRM1 (0.75) | OPRM1NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL31114390 | 0.87 | OPRM1 (0.64) | OPRM1NTSR2NTSR1SORT1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070041972-A1 | Antibodies and fusion proteins that include engineered constant regions | ALEXION PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | claimed |
| US-9493551-B2 | Antibodies containing therapeutic TPO/EPO mimetic peptides | ALEXION PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9409964-B2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150004700-A1 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2752427-A1 | Antibodies containing therapeutic TPO/EPO mimetic peptides | Alexion Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-8771932-B2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8674082-B2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120070434-A1 | ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES | ALEXION PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1642910-B1 | Rationally designed antibodies | ALEXION PHARMA INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2401302-A1 | ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES | ALEXION PHARMACEUTICALS, INC. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-1642910-A1 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1635872-A2 | ANTIBODIES AND FUSION PROTEINS THAT INCLUDE ENGINEERED CONSTANT REGIONS | ALEXION PHARMACEUTICALS, INC. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1370589-B1 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMA INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1589034-A2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005082004-A2 | RATIONALLY DESIGNED ANTIBODIES HAVING A DOMAIN-EXCHANGED SCAFFOLD | ALEXION PHARMACEUTICALS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005007809-A2 | ANTIBODIES AND FUSION PROTEINS THAT INCLUDE ENGINEERED CONSTANT REGIONS | ALEXION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1498429-A2 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040253242-A1 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20030232972-A1 | Rationally designed antibodies | ALEXION PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030049683-A1 | Immunoglobulin for use in human therapeutics and diagnostics | ALEXION PHARMACEUTICAL, INC. | 2003-03-13 | — | — | US | disclosed |